The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: Bristol-Myers Squibb

Monday Biotech Deal Review: February 7, 2011

Welcome to your Monday Biotech Deal Review for February 7, 2011.  It was a fairly busy week for Canadian biotech – Angiotech has followed suit in the U.S. on the heels of last week’s CCAA filing, a number of acquisitions were announced, and there was some activity in biotech licensing.  Read on to learn more. 

Monday Biotech Deal Review: October 11, 2010

Happy (Canadian) Thanksgiving!  This Monday Biotech Deal Review reports that it was a bad week for turkeys and a bit of a slow week on the biotech front, but read on to learn about some interesting collaborations, allegations and corporate immigrations.

Bristol-Myers Squibb Strikes $2.1 billion Deal for Medarex

Great news for Medarex shareholders from BMS’ $16/share offer yesterday, which clocks in at a 90% premium over Wednesday’s close.  Reports cite the value of ipilimumab, a late-stage cancer therapy being advanced as a new treatment for metastatic melanoma, as well as the value of Medarex’s transgenic mouse platform to make human antibodies. However, the [...]

Trends Update — Comparative Effectiveness and Personalized Medicine: Genetic Test Identifies Patient Subpopulation for Benefit, Avoids Wasted Money and Time for Others on Erbitux, Vectibix

This is exactly how personalized medicine and comparative effectiveness can interact to benefit patients, pharma companies and payors: data shows that patients with KRAS mutations don’t benefit from anti-EGFR antibody meds Erbitux or Vectibix; the FDA approves a labeling change identifying the patients who won’t benefit; payors see costs savings from eliminating pointless prescriptions; patients [...]

Wednesday Brain Dump: Around the World Edition

Click on the map points for each story, or just read on

M&A Update

Following our last update, there have been a considerable number of bio/pharma M&A developments, so to bring you up to speed

It’s Raining M&A

Pfizer-Wyeth is certainly the biggest headline (see here for info on those companies in Canada), but it seems like a very popular time to be shopping.

Follow

Get every new post delivered to your Inbox.

Join 84 other followers